U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Medical indications

Davis, Bruce H.; Foucar, Kathy; Szczarkowski, Wlodek; Ball, Edward D.; Witzig, TE; Foon, Kenneth A.; Wells, Denise A.; Kotylo, Pat; Johnson, Rebecca L.; Hanson, Curtis A.; Bessman, David

doi:10.1002/(sici)1097-0320(19971015)30:5<249::aid-cyto6>3.0.co;2-c

Cited by 59 publications

(22 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tests were performed in accordance with the recommendations of the US-Canadian Consensus Conference on the Immunophenotypic Analysis of Hematologic Neoplasia by Flow Cytometry. 20,21 Anti-CD52 MoAb was obtained from Serotec (Raleigh, NC, USA).…”

Section: Methodsmentioning

confidence: 99%

Phenotypic transformation of CD52pos to CD52neg leukemic T cells as a mechanism for resistance to CAMPATH-1H

et al. 2002

View full text Add to dashboard Cite

Immunotherapy utilizing CAMPATH-1H for patients with chemotherapy-refractory chronic lymphocytic leukemia has yielded encouraging results with many reports of complete remission. Here we report the outcome of two patients with CD4-positive T cell prolymphocytic leukemia treated with CAM-PATH-1H. Both patients responded rapidly to treatment and subsequently developed CD4 lymphopenia. One patient remained in complete remission after 14 weeks of treatment. Serial peripheral blood flow cytometry revealed that the CD52 antigen was present throughout treatment. The other patient who was initially CD52-positive, became CD52-negative after 6 weeks of treatment, and developed progressive symptoms of T cell prolymphocytic leukemia. Immunotherapy was stopped, chemotherapy proved futile, and the patient died. This change in phenotype from CD52-positive to -negative during CAM-PATH-1H therapy points out a need to develop strategies for maintaining antigenic expression during monoclonal antibody therapy. Leukemia (2002) 16, 861-864.

show abstract

Section: Methodsmentioning

confidence: 99%

Phenotypic transformation of CD52pos to CD52neg leukemic T cells as a mechanism for resistance to CAMPATH-1H

et al. 2002

View full text Add to dashboard Cite

show abstract

“…[6][7][8][9][10] The procedure evolved over the last two decades from microscopic evaluation of antibody staining to flow cytometry, which is now recognized as the preferred method for data analysis. [8][9][10][11][12][13] For Nigeria to meet the millennium development goals in health programs in general and specifically in the management of HM, a giant stride will have to be taken not only to improve manpower development in cancer diagnosis and treatment but also in equipping our specialist hospitals with modern equipment of which flow cytometry is one part.…”

Section: Current Status Of Impt In Ibadan Nigeriamentioning

confidence: 99%

“…Extensive studies [6][7][8][9][10][11][12][33][34][35][36][37] have been done on the factors that affect the results of immunophenotyping, including: 1. The type and quality of samples.…”

Section: The Principles Of Fcmentioning

confidence: 99%

Flow cytometric immunophenotyping of hematological malignancies: the way forward in Nigeria

Olaniyi¹

2011

PLMI

View full text Add to dashboard Cite

Aim: This review serves to awaken the interest of stakeholders involved in research and management of hematological malignancies (HM) in the efficacy of flow cytometry in the immunophenotypic characterization of leukemias and lymphomas. This well-defined characterization plays a crucial role in diagnosis, classification, prognostic evaluation, and detection of minimal residual disease, in the context of clinical features and morphological diagnosis. Methodology: Relevant literature was retrieved to highlight the principles of operation of flow cytometry, indications and applications, derivable clinical information and clinical relevance, sources of error, and necessary steps towards definitive and specific diagnosis of each HM. Conclusion: Flow cytometric immunophenotyping (FCIMPT) of HM is highly demanding and capital intensive but its usefulness in profiling these exceptionally heterogeneous disorders, and allowing proper classification along the latest WHO classification guidelines, thereby paving the way for targeted therapy and clinical trial-driven management, significantly outweighs the cost, which can be fully recovered if properly managed. In a low-resource setting like Nigeria, limited immunohistochemistry serves to bridge the gap in technological advancement.

show abstract

“…Furthermore, normal and pathological fluorescence (FL) patterns must be characterized for the diagnostic interpretation of specific combinations of antigens. In an attempt to standardize these procedures, extensive recommendations have been published in Europe (9) and in America (10)(11)(12)(13)(14)(15)(16). Despite these efforts, there are still many concerns regarding everyday practice, and wide variations in operating procedures among laboratories involved in the flow cytometric immunophenotyping of acute leukemias still exist.…”

mentioning

confidence: 99%

Normal lymphocytes from leukemic samples as an internal quality control for fluorescence intensity in immunophenotyping of acute leukemias

Ratei

Karawajew

Lacombe

et al. 2005

Cytometry Part B Clinical

View full text Add to dashboard Cite

U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Medical indications

Cited by 59 publications

References 144 publications

Phenotypic transformation of CD52pos to CD52neg leukemic T cells as a mechanism for resistance to CAMPATH-1H

Phenotypic transformation of CD52pos to CD52neg leukemic T cells as a mechanism for resistance to CAMPATH-1H

Flow cytometric immunophenotyping of hematological malignancies: the way forward in Nigeria

Normal lymphocytes from leukemic samples as an internal quality control for fluorescence intensity in immunophenotyping of acute leukemias

Contact Info

Product

Resources

About